Nordic Bioscience’s Post

We are going to #UEGWeek! Our gastroenterology team will have a strong presence at UEG Week 2024 in Vienna, with four oral presentations and two poster presentations showcasing our latest research in gastrointestinal health. In addition, we will be happy to discuss how our CPa9-HNE Serum Calprotectin biomarker can contribute to IBD programs, which has now received a Letter of Support for its role in monitoring disease and neutrophil activity in Inflammatory Bowel Disease (IBD). 📩 Reach out to Elijah Aighobahi connect or Joachim H. Mortensen if you wish to learn more! Martin Pehrsson, Ph.D Marta S. Alexdóttir Thomai Tsapanou-Katranara #IBD #DrugDevelopment #Colitis #IngestTheBest

We are pleased to share that our CPa9-HNE blood-based biomarker assay has received a Letter of Support from the FDA. CPa9-HNE, also known as the Nordic Serum Calprotectin biomarker, measures activated neutrophils and is now recommended for inclusion in studies on inflammatory bowel disease (IBD). CPa9-HNE may enhance clinical trials by identifying patients with moderate to severe active ulcerative colitis or Crohn’s disease, potentially reducing the need for unnecessary endoscopies. The FDA encourages formal qualification of CPa9-HNE as an enrichment biomarker through analytical validation and data sharing across clinical trials to advance its development as a drug development tool. ➡️ Read the full news and the Letter of Support on the link below: https://lnkd.in/e_7TSxr9 #FDA #IBD #LetterOfSupport #DrugDevelopment #Neutrophils #CPa9HNE

September is pulmonary fibrosis (PF) awareness month—a progressive lung disease that affects over 200,000 people in the United States alone. PF causes scarring of lung tissue, leading to severe breathing difficulties and reduced quality of life. At Nordic Bioscience, we are dedicated to advancing the development of biomarkers that provide deeper insights into disease progression in pulmonary fibrosis. Together with our collaborators, we contributed to the Lancet publication: “Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.” This research represents a step forward in identifying endotypes that can help improve the monitoring of the disease and guided therapy, ultimately enhancing patient care. We hope our findings encourage continued research and collaboration, working together to make a lasting impact! 📰 Publication: https://lnkd.in/dgYZG5mT #pulmonaryfibrosis #pulmonary #IPF #fibrosis #PulmonaryFibrosisMonth Diana Julie Leeming Filipa Simões Jannie M. B. Sand Sarah Rønnow Annika Hummersgaard Hansen, PhD

We’re thrilled to announce that we’ll be presenting new data #ERS in Vienna (Sep 7-11)! We will showcase findings from our SiaJ (Scar in a Jar) model where we’ve tested treprostinil. Our research demonstrates its significant impact on fibroblast activity, a critical factor in developing effective treatments for Idiopathic Pulmonary Fibrosis (IPF).   Understanding fibroblast behavior is crucial in IPF progression, and our results could offer valuable insights for future therapeutic applications. We believe this work has great potential to further enhance the success for future drug development.   If you're attending ERS, reach out to Sarah Rønnow to learn more and explore potential collaborations. Diana Julie Leeming Filipa Simões Annika Hummersgaard Hansen, PhD #drugdevelopment #IPF #lung #clinicaltrials #ERS2024

Agenda for the upcoming obesity webinar, co-hosted with The Extracellular Matrix Pharmacology Congress! Three in-depth talks will delve into several closely related metabolic processes that tie together various organ functions, and of course, the extracellular matrix is the center theme. The presentations will cover the following topics and more: ✅ Metabolic activation and de-activation of fibroblasts ✅ ECM production of fibroblast and the relation to outcomes in heart, liver and kidney diseases ✅ Pharmacological modulation of fibroblast activation and the benefit for patients ➡️ Sign up while we have seats open: https://lnkd.in/ddse2UqZ Morten Karsdal Diana Julie Leeming Federica Genovese Nicholas Willumsen Rune Vestermark Signe Hausgaard Larsen Daniel Gabor #webinar #obesity #metabolicdisease #liver #heart #kidney

We are excited to be part of the 8th IPF Summit (Boston, MA), August 20-22! Diana (Senior Director of Pulmonary a Hepatic Research) and Sarah (Associate-Director of Pulmonary Research) will be there to discuss the latest advancements in the IPF field and how our biomarker technologies can benefit drug developers. In addition, Diana will take the stage at 8.30 AM on August 22nd. She will present "Decoding Prognosis and Pharmacodynamics in Lung Fibrosis: Insights from the FIB-NIT panel". In her talk, you can expect to hear about: ✔️ Integration of biomarkers for improved clinical outcomes ✔️ Understanding the extracellular matrix in lung fibrosis ✔️ Translational biomarkers for preclinical model applications Will you be joining us there? Reach out to Sarah Rønnow! #IPFSummit #Boston #Conference #lung #pulmonary

It's the middle of August, we've just reached 17.000 followers (thank you for your trust in us!) and we are BACK with the next educational webinar experience! 🥳 This time, the focus will be obesity and its related organ disorders; as usual, the event is free to participate in. Sign up today ➡️ https://lnkd.in/ddse2UqZ Morten Asser Karsdal Federica Genovese Nicholas Willumsen Diana Julie Leeming Rune Vestermark Mayuur Bajaj Signe Hausgaard Larsen Daniel Gabor #webinar #obesity #pharmacology #kidney #heart #liver